STOCK TITAN

CG Oncology officer plans $499K stock sale

Officer Ambaw Bellete files a Rule 144 notice to sell 6,532 CG Oncology shares after reporting substantial prior sales over the past three months.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

CG Oncology, Inc. (CGON) received a Rule 144 notice from officer Ambaw Bellete covering a proposed sale of 6,532 shares of common stock through Morgan Stanley Smith Barney, with a reported aggregate market value of $499,698.00, around September 17, 2026. The notice reports 88,640,375 shares of common stock outstanding.

Bellete also reports multiple prior sales of CG Oncology common stock in the past three months under Rule 144, including 100,000 shares sold on August 19, 2026 for $7,954,105.00 and several other transactions ranging from a few thousand to 50,000 shares each.

Positive

  • None.

Negative

  • None.
Shares to be sold under Rule 144 6,532 shares Proposed sale of CG Oncology common stock by officer Ambaw Bellete
Aggregate market value of planned sale $499,698.00 Reported value for the 6,532 shares covered by the Rule 144 notice
Shares outstanding 88,640,375 shares Reported outstanding CG Oncology common stock in the Rule 144 notice
Sale on August 19, 2026 100,000 shares for $7,954,105.00 Largest single reported CGON sale by Ambaw Bellete in past three months
Sale on August 31, 2026 50,000 shares for $3,775,250.00 Reported CGON sale by Ambaw Bellete
Sale on July 15, 2026 52,438 shares for $3,816,007.65 Earliest reported sale in the three‑month lookback period
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
aggregate market value financial
"6532 | 499698.00 | 88640375 | 09/17/2026"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
stock option exercise financial
"Common | 09/17/2026 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
Securities To Be Sold regulatory
"144: Securities To Be Sold Common | 09/17/2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Rule 144 filing disclose for CGON?

The notice discloses that Ambaw Bellete, an officer of CG Oncology, plans to sell 6,532 shares of common stock under Rule 144, with a reported aggregate market value of $499,698.00, and that there are 88,640,375 shares outstanding.

How many CGON shares is Ambaw Bellete planning to sell under this Rule 144 notice?

Ambaw Bellete is planning to sell 6,532 shares of CG Oncology common stock under this Rule 144 notice, with a reported aggregate market value of $499,698.00, and the transaction is associated with a stock option exercise for cash dated September 17, 2026.

What recent CGON share sales by Ambaw Bellete are reported in the last three months?

The filing lists multiple sales, including 100,000 shares for $7,954,105.00 on August 19, 2026 and 50,000 shares for $3,775,250.00 on August 31, 2026, along with several other transactions between July 15 and September 11, 2026.

How many CGON shares are reported as outstanding in the Rule 144 notice?

The Rule 144 notice reports that 88,640,375 shares of CG Oncology common stock are outstanding. This figure serves as a baseline share count and is separate from the 6,532 shares covered by the planned sale.

Through which broker will the CGON Rule 144 shares be sold?

The notice states that the 6,532 CG Oncology shares covered by the Rule 144 filing are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with the securities listed for trading on NASDAQ.

What is the nature of the CGON shares to be sold by Ambaw Bellete?

The securities are common stock of CG Oncology to be sold following a stock option exercise for cash dated September 17, 2026, as reported in the “Securities To Be Sold” section of the Rule 144 notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading